Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF+DAC+BF vs G-CSF+DAC+BUCY in High-risk MDS
NCT05453552Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of fludarabine in myelodysplastic syndrome (MDS), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
fludarabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05453552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453552.